z-logo
open-access-imgOpen Access
Attenuation of Reperfusion Injury by the Antioxidant n-Propyl Gallate
Author(s) -
Aruni Bhatnagar
Publication year - 1995
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-199509000-00001
Subject(s) - preload , ischemia , perfusion , cardiology , ventricular pressure , rate pressure product , lactate dehydrogenase , propyl gallate , medicine , coronary perfusion pressure , chemistry , hemodynamics , heart rate , anesthesia , blood pressure , antioxidant , biochemistry , resuscitation , cardiopulmonary resuscitation , enzyme
We studied the effects of n-propyl gallate (n-PG) on Langendorff preparations of isolated rat hearts. Perfusion of the hearts with Krebs-Henseleit (KH) solution containing 20 microM n-PG did not cause a statistically significant change in either left ventricular systolic pressure (LVSP), end-diastolic pressure (LVEDP), developed pressure (LVDP), or heart rate (HR), indicating that n-PG has little acute myocardial toxicity. The effects of n-PG on the reperfused and ischemic myocardium were tested in hearts subjected to 15-min global P4 the ischemic hearts with KH buffer resulted in the recovery of the LVDP to 66 +/- 7% (mean +/- SEM, n = 11) and the recovery of the rate-pressure product (RPP) to 65 +/- 7% of their preischemic values. The LVEDP of the reperfused hearts was 30 +/- 5 mm Hg as compared with the preischemic LVEDP of 5.2 +/- 0.9 mm Hg. The difference between the coronary flow rate of the preischemic hearts (15.4 +/- 0.8 ml/min) and the reperfused hearts (13.9 +/- 0.9 ml/min) was not statistically significant (p > 0.05). Addition of n-PG, at the time of reperfusion, resulted in with KH buffer containing 20 microM n-PG had LVEDP of 6.2 +/- 0.4 mm Hg, and both LVDP and RPP recovered to 92 +/- 4% of the preischemic control.(ABSTRACT TRUNCATED AT 250 WORDS)

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here